Optimization of the in Vitro and in Vivo Properties of a Novel Series of 2,4,5-Trisubstituted Imidazoles as Potent Cholecystokinin-2 (CCK<sub>2</sub>) Antagonists
作者:Ildiko M. Buck、James W. Black、Tracey Cooke、David J. Dunstone、John D. Gaffen、Eric P. Griffin、Elaine A. Harper、Robert A. D. Hull、S. Barret Kalindjian、Elliot J. Lilley、Ian D. Linney、Caroline M. R. Low、Iain M. McDonald、Michael J. Pether、Sonia P. Roberts、Nigel P. Shankley、Mark E. Shaxted、Katherine I. M. Steel、David A. Sykes、Matthew J. Tozer、Gillian F. Watt、Martin K. Walker、Laurence Wright、Paul T. Wright
DOI:10.1021/jm0490686
日期:2005.11.1
The systematic optimization of the structure of a novel 2,4,5-trisubstituted imidazole-based cholecystokinin-2 (CCK(2)) receptor antagonist afforded analogues with nanomolar receptor affinity. These compounds were now comparable in their potency to the bicyclic heteroaromatic-based compounds 5 (JB93182) and 6 (JB95008), from which the initial examples were designed using a field-point based molecular
新型的2,4,5-三取代的咪唑基胆囊收缩素2(CCK(2))受体拮抗剂的结构的系统优化提供了具有纳摩尔受体亲和力的类似物。这些化合物的效价现在与基于双环杂芳族化合物5(JB93182)和6(JB95008)的效价相当,后者使用基于场点的分子建模方法设计了初始实例。通过抑制五肽胃泌素刺激的清醒犬的酸分泌可以判断,它们也具有口服活性,这与基于双环杂芳香族化合物的化合物(由于胆道消除而无效)相反。通过用醚氧置换特定的亚甲基来增加亲水性,如3-[5-(金刚烷-1-基氧甲基)-2-环己基-1H-咪唑-4-羰基]氨基}苯甲酸中的苯甲酸(53)一样,对受体亲和力的影响很小,但显着提高了口服药的效力。 。比较血浆药代动力学和对十二指肠内推注53和6后五肽胃泌素刺激的酸输出的抑制作用,表明53吸收良好,半衰期更长,并且不受早期系列的消除途径的影响。